Update on nonsmall cell lung cancer.
ER 3 INSERM "Cancers et Populations", Service de Pneumologie and Intergroupe Francophone de Cancérologie Thoracique (IFCT), CHU Côte de Nacre, Université Caen-Basse Normandie, Caen, France. zalcman-g@chu-caen.fr
G
G
Zalcman
E
E
Bergot
E
E
Lechapt
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068258:Bevacizumab; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D004359:Drug Therapy, Combination; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab